Equally Knocking on the Door of Medical Breakthroughs: Safety and Efficacy of a New Anti-Cancer Drug Pamica (PICNH₂Ca) for Late Stage Cancer Patients

The composition of Pamica (PICNH2Ca2) is dsRNA polyI:C, non-biotics amino compounds and CaCl2. It is the second generation noncytotoxic product of PICKCa (PIKA) adjuvant which was found effective in phase II clinical trial for PICKCa rabies vaccine and phase I trial for PICKCa hepatitis B vaccine in Singapore. With their knowledge and consent, cancer patients, regardless of their tumor types or performance status (ECOG above 5 or ECOG > 20), who were unresponsive to standard treatment, were treated free of charge with Pamica by injection or nasal spray. The primary results indicated that Pamica had no side effect except for a few cases of local pain in the site of injection and appeared to markedly improve cancer patients’ appetite, physical strength, quality of life and extended patients’ life for months and counting. These preliminary findings underlined promise of this potentially life-saving drug. In the hope of cooperating with the proper authorities, companies, and hospitals to benefit patients at the earliest opportunity, we share our findings in this paper.

用非特异性免疫促进剂开启抗病毒抗肿瘤治疗革命大门

目的:本文通过帕米卡®在治疗荷瘤小白鼠上的安全性和显著效果,阐明了使用非特异性免疫促进剂作为广谱抗肿瘤抗病毒治疗的可行性。方法:用肺癌、乳腺癌、黑色素瘤细胞造成荷瘤小白鼠模型,再用帕米卡制剂隔天注射或喷鼻0.1~0.2 ml/次(3 mg/ml)治疗并设阳性对照药及溶媒阴性对照,观察对小白鼠肿瘤抑制率及其瘤体重量、肿瘤转移、荷瘤小白鼠脾重,体重、存活数等。结果:帕米卡对几种荷瘤小白鼠有效性统计学测定效果与阴性对照比较p 【0.05~0.0001,甚至优于阳性对照PD1、紫杉醇(PTX)法定抗癌药。结论:帕米卡非特异性免疫制剂对几种荷瘤小白鼠具有安全性良好和极其显著的治疗效果,表明了这种新思路和新方法抗肿瘤抗病毒是可行的,具有重大现实意义。